🔗 Share this article

As the United States undertakes unprecedented revisions to its immunization guidelines, a particular individual appears in a surprising turn: Høeg, a Danish American sports physician and public health researcher who first made her name by questioning COVID-19 shots in the global health crisis and has concentrated on alleged deaths following Covid immunization in her short position at the Food and Drug Administration.

Scheduled Changes to Childhood Immunization Program

Agency leaders had intended to reveal radical revisions to the pediatric vaccine schedule earlier this month, bringing the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US at odds with many the world with insufficient data for improved outcomes. This reveal has been postponed until the coming year.

Rather than Vinay Prasad, Høeg is listed to present at the meeting. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth individual to lead the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Prasad strengthen their influence at the agency – and it points to a increased emphasis upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has often pushed for halting some childhood shot schedules in the US in order to be more in line with the Danish model, a society with universal health coverage and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccination policy – typically the purview of Prasad, director of the FDA’s CBER – rather than drug regulation.

Doubts Over Expertise

The appointee has little discernible background in pharmaceutical research, approval processes or management, which has been standard for former heads of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since spring.

“It seems she lacks to have any of the qualifications” for running the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in managing a major agency. She lacks background in pharmaceutical oversight.”

Previous commissioners of CBER would “grasp legal statutes and the research of drug development”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that previous people who led the center have had.”

CDER has an vast range of responsibilities at the agency, Woodcock stated.

“The public just zeroes in on the innovative therapies, but the off-patent medication office authorizes numerous generic medications. There’s a biologic copycat branch, OTC medication office and so forth, and all of those have to be looked after,” Woodcock explained. “The thing you neglect, that is the part that I always told people is going to bite you.”

Additionally, a significant administrative aspect to the position, which oversees over 5,000 personnel. “It’s a massive leadership role, if you execute it properly,” she concluded.

Official Statement and Controversial Initiatives

Regarding concerns about Dr. Høeg's qualifications and whether this appointment represents greater collaboration among agency officials on immunizations, a representative stated that the “concerns are based on inaccurate premises”.

“Her experience matches the duties of her position,” the representative stated, noting the time Dr. Høeg spent counseling the agency head on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched priority voucher program, a disputed expedited therapy clearance system that apparently troubled her predecessors. “How are these therapies being chosen for this voucher program? Who takes the calls?” Howard asked. “There’s a lot of secrecy occurring at the agency right now.”

Overall, he remarked, “the FDA looks to be trending towards more relaxed oversight of most medications, aside from vaccines.”

Documented Past Work on Immunizations

With immunizations, Høeg has a more documented, if problematic, track record, Howard have noted. She released a study using unconfirmed crowd-sourced reports to estimate the incidence of heart inflammation after Covid vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccines are riskier than they are.

Among her “policy goals” for the new government included altering rules for new vaccines and discontinuing “non-essential” vaccines, she remarked after the election on a audio program. At the agency, Dr. Høeg has according to sources proposed barring teenage boys from receiving Covid vaccinations.

“She’s an complete ideologue who begins with her beliefs and works backwards to retrofit the data in a extremely disingenuous, fraudulent manner,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|